Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
[The effects of ticlopidine and nifedipine on platelet aggregation in patients with obliterating arteriopathy of the lower limbs].
This paper evaluates the antiaggregant action of ticlopidine and nifedipine in patients with obliterate arteriopathy in inferior limbs of arteriosclerotic etiology ( OAIL ) . They were established 4 study groups : control , with health volunteers without treatment ( N = 10 ) ; patients treated with placebo ( n = 11 ) ; patients treated with 500 mg/day of ticlopidine ( n = 12 ) and treated with 30 mg/day of nifedipine ( n = 12 ) . The last 3 groups the treatment duration was 30 days . It was studied the platelet aggregatory activity against ADP and collagen , before drug administration and at 15 and 30 days post-treatment . Our results suggest that : Platelet aggregation is increased in patients with AOMI compared with that observed in the control group . Ticlopidine inhibits platelet aggregation induced by ADP , but not that induced by collagen . Nifedipine does n't produce any effect on platelet aggregation
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .